Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy

Heredity (Edinb). 2020 May;124(5):619-620. doi: 10.1038/s41437-020-0314-z. Epub 2020 Apr 6.
No abstract available

MeSH terms

  • Amides / pharmacology
  • Amides / therapeutic use
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use*
  • Betacoronavirus / drug effects
  • Betacoronavirus / genetics*
  • COVID-19
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / virology
  • Humans
  • Models, Genetic
  • Mutation Accumulation*
  • Mutation*
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / virology
  • Pyrazines / pharmacology
  • Pyrazines / therapeutic use
  • SARS-CoV-2

Substances

  • Amides
  • Antiviral Agents
  • Pyrazines
  • favipiravir

Supplementary concepts

  • COVID-19 drug treatment